Digital Programme

This year’s digital AMR Conference will be an international forum to discuss AMR in the context of COVID-19 and beyond.

Each day will cover a focus topic with LIVE sessions and high-level panels:
Lessons learned from COVID-19 | Business Models & Policy Incentives | Global Markets | Financing & Investing | Outlook & Policy Roadmap

Registered participants will have access to on-demand versions of all sessions.

Overall theme of the day: Lessons learned from COVID-19

09:45–10:45 CEST

Additional programme:
BEAM Alliance meet-up (for members only)

11:00–12:30 CEST

Additional programme:
Expert campus | Top 10 mistakes in antibacterial development 

Jointly organised by Novo REPAIR Impact Fund, CARB-X, GARDP and Wellcome Trust

                      

Moderator: Ursula Theuretzbacher – Founder, CEFAIA

Speaker: 

  • Peter Warn – SVP, Anti-infective Discovery, Evotec
  • Richard Knight – Director & Co–founder, ApconiX
  • Aleksander Danilovski – CSO & Senior Vice President Global R&D and Regulatory Affairs, Xelia
13:30–15:00 CEST

Opening Session | Infectious diseases in the global spotlight: Why COVID-19 has an impact on AMR

Moderator: Deborah A O’Neil – CEO, NovaBiotics Ltd & Board Member, BEAM Alliance

Speakers:

  • Manica Balasegaram – Executive Director, GARDP
  • Christian Drosten – Director of Institute of Virology, Charité (tbc)
  • Jordi Vila – Head of Service, Biomedical Diagnostic Center, Microbiology, Hospital Clinic Barcelona (tbc)
15:15–16:15 CEST

Diagnostics | Why diagnostics are a gamechanger to control a pandemic and what this means for combatting AMR

All speakers will be announced soon.

16:30–18:00 CEST

One Health | Why it is more important than ever to think cross-sectoral

Moderator and Speaker:
Ghada Zoubiane – Head of Partnerships and Stakeholder Engagement, ICARS

Speakers:

  • Peers Davies – Senior Lecturer in Livestock Health and Welfare Epidemiology and Population Health, University of Liverpool, CEIDR
  • Elmar Nimmesgern – Secretariat Lead, Global AMR R&D Hub
  • Timo Minssen – Founder and Managing Director, Center for Advanced Studies in Biomedical Innovation Law (CeBIL)
  • Viviana Muñoz-Tellez – Coordinator, Development, Innovation and Intellectual Property Programme (DIIP), South-Center
ALL DAY Virtual 1:1 Partnering Meetings

Overall theme of the day: Business Models & Policy Incentives

09:30 – 11:00 CEST

Expert campus | How to accelerate AMR drug discovery & development

Moderation: Isabelle Bekeredjian-Ding – Head of Department, Paul-Ehrlich Institut

Speakers:

  • Claus Stie Kallesøe – CEO & Co-founder, grit42
  • Dirk Bumann – Professor for Infection Biology, The Center for Molecular Life Sciences, University of Basel
  • Dave Madge – Vice President, Research Service Division, WuXi AppTec
  • N.N., AiCuris
13:30–15:00 CEST

Business models | The AMR company of the future – Which route to success

Sponsored by:

Moderator: Erin Duffy – Chief of Research & Development, CARB-X

Speakers:

  • Jonathan Butcher – Head of Business Development, BioVersys AG
  • Cherif Bousselham – Senior Vice President, Head of Sales, EMEA, Accelerate Diagnostics Inc.
  • Jean-Pierre Paccaud – Director of Business Development and Corporate Strategy, GARDP
  • Kenneth Bradley – Global Head, Infectious Disease Discovery, Roche
15:15–16:15 CEST

SME approach | How to develop strategic decisions in a challenging and global AMR market

Sponsored by:

Moderator: Gökhan Batur – CEO, Polyphor Ltd

Speakers:

  • Peter Beyer – Senior Advisor Department of Essential Medicines & Health Products, WHO
  • Erin Duffy – Chief of Research & Development, CARB-X
  • Holger Zimmermann – CEO, AiCuris
16:30–17:45 CEST

AMR pull incentives | Will COVID-19 speed up or slow down implementation?

Moderator: Kathy Talkington, Director Health Programs, Pew Charitable Trust

Speakers:

  • Colm Leonard – Clinical Advisor/Consultant, NICE
  • Kevin Outterson – Professor of Law & Executive Director, CARB-X
  • Elmar Nimmesgern – Secretariat Lead, Global AMR R&D Hub
  • Daniel Berman – Lead of the Global Health Team, Longitude Prize / Nesta
17:45–18:45 CEST

Diagnostics | Novel solutions to solve the reimbursement challenge

Moderator: Till Bachmann – Deputy Head of Infection Medicine and Personal chair of Molecular Diagnostics and Infection, University of Edinburgh

Speakers:

  • Philippe Cleuziat – Innovation Program Senior Director, bioMérieux, VALUE-Dx
  • Colm Leonard – Clinical Advisor/Consultant, NICE
  • Jesus Rueda Rodriguez, Director International Affairs, EDMA, Eucomed & MedTech Europe (tbd)
  • Daniel Berman – Lead of the Global Health Team, Longitude Prize / Nesta
19:00–20:00 CEST

Expert Campus | Diagnostics in clinical trial settings

Supported by:

Moderator: Daniel Berman – Lead of the Global Health Team, Longitude Prize / Nesta

Speakers:

  • Kwangmin Son – Co-founder & CEO, Phast Corp.
  • Michael Lobritz – Translational Project Leader, Roche
  • Laurenz Kellenberger, CSO, Basilea
  • Cassandra Kelly-Cirino, Director of Emerging Threats,  FINDDx  (tbd)
ALL DAY Virtual 1:1 Partnering Meetings

Overall theme of the day: Global Markets

09:15–10:45 CEST

Expert campus | Focus on tuberculosis

Speakers:

  • Michel Pieren – Project Manager, BioVersys AG, CH
  • Florian Kloss – Head, Hans Knöll Institute (HKI), GER 
  •  Michael Hoelscher – Network Coordinator, Ludwig-Maximilians-University Munich (LMU), GER 
11:00–12:30 CEST

Expert campus | Focus on TB diagnostics

Supported by:

Moderation: Anita Suresh – Head of Sequencing, FINDx

Speakers:

  • Akos Somoskovi – Director of Clinical Science, Roche
  • Sebastian Dümcke – CEO, Clemedi AG 

Further speakers to be announced soon. 

13:30–15:00 CEST

Global markets | Why we need to think global to tackle AMR

Moderator: Marc Lemonnier – Founding CEO, Antabio SAS

Speakers:

  • Heiman Wertheim – Head of Clinical Microbiology Department, Radboud University Medical Center
  • Anand Anandkumar – CEO, Bugworks
  • Alexandra Cameron – Senior Technical Manager Strategy Team, UNITAID
  • Bruce Altevogt, Vice President and Head External Medical Engagement, Hospital Business Unit, Pfizer
  • Gemma Buckland Merrett – AMR Science and Research Lead, Wellcome Trust 
15:15–17:00 CEST

Clinical trials | Why global networks are crucial to speed up late stage clinical development

Speakers:

  • Seamus O’Brien – R&D Director, GARDP
  • Tim Jinks – Head of Antibiotic Resistance Infections Program, Wellcome Trust
  • Florence Séjourné – CEO, DaVolterra & President, BEAM Alliance
  • Kamini Walia – Head of AMR, ICMR, Government of India
17:45–18:30 CEST

Regulatory perspective | Current status and the post-COVID outlook for antibiotic clinical trials & approvals

Speakers:

  • Sumathi Nambiar – Director Division of Anti-Infective Products, Office of Infectious Diseases, FDA
  • Radu Botgros – Scientific Officer, Anti-infectives and Vaccines, Scientific and Regulatory Management Department, EMA (tbc)
ALL DAY Virtual 1:1 Partnering Meetings

Overall theme of the day: Financing & Investing

09:45–10:45 CEST

Start-up campus | Live pitches with jury voting hosted by Novo Repair Impact Fund

All speakers will be announced soon.

11:00–12:00 CEST

SME campus (Part I) | Focus on therapeutics

Speakers:

12:00–13:00 CEST

SME campus (Part II) | Focus on diagnostics

Moderation:
Betsy Wonderly Trainor, Alliance Manager, CARB-X

Speakers:

  • Peter Haug – CFO & Co-Founder, Head of Business Development & Licensing, Noscendo GmbH
  • Piotr Gastrecki – CTO, ScopeFluidics
  • Rosemarie Preyer – GenID GmbH
13:30–15:00 CEST

Financing resistance | Why new investors are urgently needed and where they come from

Moderator: Peter Beyer – Senior Advisor Department of Essential Medicines & Health Products, WHO

Speakers:

  • Thomas Cueni – Director General, IFPMA
  • James Anderson – Head of Corporate Government Affairs, GSK
  • Silas Holland – Director Global Policy, MSD
  • Aleks Engel – Partner, Novo Holdings (Novo Seeds) & Director, REPAIR Impact Fund at Novo Holdings
15:15–16:15 CEST

Spotlight on UK | The Investor Year of Action on AMR

Sponsored by:

  

16:30–17:30 CEST

Behind the scenes | Investors’ townhall meeting

Moderator: Erin Duffy – Chief of Research & Development, CARB-X

Speaker:

  • Aleks Engel – Partner, Novo Holdings (Novo Seeds) & Director, REPAIR Impact Fund at Novo Holdings
  • Uzma Choudry – VC Investor at Octopus Ventures
  • Abigail Herron, Global Head of Responsible Investment, Aviva Investors
  • N.N, AiCuris
17:45–18:30 CEST

Expert campus | Perspective on late stage clinical development

Moderation:
Henry F. Chambers – MD Professor of Medicine, Emeritus
University of California, & Principal investigator ARLG, NIH (tbd)

Speakers

  • Laurenz Kellengerger – CSO, Basilea
  • Patrick Velicitat – CMO, Allecra 
ALL DAY Virtual 1:1 Partnering Meetings

Overall theme of the day: Outlook & Roadmap

09:30–10:45 CEST

Expert campus | Animal Health

Speakers:

  • Klaus Hellmann – Klifovet AG
  • Harald Peter – Fraunhofer IZI-BB
  • Christophe Chatain – Executive assistant & Sales Manager, Vetophage
  • Mai Huong Chatain-Ly -President & Scientific Director, Vetophage
  • Hosny El-Adawy – Institute of Bacterial Infections and Zoonoses, Friedrich-Loeffler-Institut (FLI) 
11:00–12:30 CEST

Expert campus | Noval approaches in Drug development

Speakers:

  • Albina Poljak – Director Business Development, PhagoMed Biopharma GmbH
  • Timothy Schulz-Utermoehl – Co-founder & Director, Pedanius Therapeutics
  • Niamh Máire Mohan – Pre-Clinical Technologist, Nuritas limited
  • Till  Schäberle – Professor, Department of Insect Biotechnology at University of Gießen &  Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)
  • Cesar de la Fuente – Machine Biology Group, University of Pensylvania
13:30–15:00 CEST

Closing session | The future of AMR: How a new post-COVID-19 policy roadmap could look like

Moderator: Marc Gitzinger – CEO & Vice-President, BioVersys AG, BEAM Alliance

Speakers:

  • Tiemo Woelken – MEP S&D German, vice-chair of European Parliament MEP Interest Group on AMR
  • Dame Sally Davies – UK Special Envoy on Antimicrobial Resistance & former Chief Medical Officer for England (tbc)
  • Ramanan Laxminarayan – founder and director of the Center for Disease Dynamics, Economics & Policy (CDDEP) (tbc)
ALL DAY Virtual 1:1 Partnering Meetings

BEAM Alliance programme committee

Marc Gitzinger

CEO, BioVersys AG, CH & Vice President Board, BEAM Alliance

Marc Lemonnier

Founding CEO, Antabio SAS

Deborah O’Neil

CEO, NovaBiotics Ltd & Board Member, BEAM Alliance